NON-INVASIVE PRENATAL TESTING (NIPT) MARKET ANALYSIS

Non-invasive Prenatal Testing (NIPT) Market Size and Trends

The Global Non-invasive Prenatal Testing (NIPT) Market is estimated to be valued at USD 4.60 Bn in 2024 and is expected to reach USD 9.11 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 10.2% from 2024 to 2031.

Key Takeaways of the Non-invasive Prenatal Testing (NIPT) Market:

• By product & service, the product segment is expected to contribute the highest share of the market with 55.1% in 2024.
• By application, the trisomy detection segment is expected to contribute the highest share of the market with 42.4% in 2024.
• By technology, the Next-Generation Sequencing (NGS)segment is expected to contribute the highest share of the market with 39.1% in 2024.
• North America is projected to top the global market with 37.3% share, followed by Asia Pacific with 27.7% share in 2024.

Market Overview:

The global non-invasive prenatal testing (NIPT) market is witnessing high growth rate owing to rising awareness about NIPT and increasing focus of key players on new product launches and approvals. Growing prevalence of Down’s syndrome and other genetic disorders in babies and rapid expansion of application areas of non-invasive prenatal testing are expected to drive the market growth during the forecast period. Furthermore, increasing preference of non-invasive techniques over invasive methods and reimbursement for NIPT in many countries have been supporting the growth of this market. However, availability of alternative diagnostic techniques and ethical concerns regarding NIPT are expected to hamper the market growth to some extent.

To learn more about this report, Request sample copy

Key Developments:

• In October 2024, Yourgene Health, a part of the Novacyt Group and a leader in molecular diagnostics, partnered with Genetix, a high-tech genetic diagnostics organization, to launch Colombia's first local non-invasive prenatal testing (NIPT) service. Utilizing Yourgene’s IONA Nx NIPT Workflow, Genetix's NipTest offers safe, fast, and accurate prenatal testing, reducing turnaround times and eliminating shipping challenges for expectant parents in the region.
• In September 2023, Yourgene Health plc, a leading provider of genomic solutions, launched the Yourgene MagBench Automated DNA Extraction Instrument and Kit for Sage customers in Asia Pacific and the Middle East. This cost-effective bench-top robotic workstation, designed for the Sage 32 NIPT Workflow, enables clinical labs to offer precise and efficient NIPT services.
• In August 2022, Natera, Inc., a pioneer in cell-free DNA testing, announced at the Canaccord Genuity Growth Conference that it had initiated the U.S. FDA pre-submission process for its Panorama NIPT. The filing targets fetal chromosomal aneuploidies and 22q11.2 deletion syndrome, highlighting Natera's commitment to regulatory compliance and advanced prenatal diagnostics.
• In September 2022, Yourgene Health plc, a leader in genomic and diagnostic solutions, received Health Sciences Authority (HSA) approval in Singapore for its IONA Nx NIPT Workflow. This approval enables clinical laboratories to offer advanced non-invasive prenatal testing (NIPT) services.
• In September 2022, Eurofins Genoma, a pioneer in advanced genetic diagnostics, introduced a non-invasive preimplantation genetic aneuploidy screening test (niPGT-A). This innovative solution provides IVF centers with a precise and reliable alternative to traditional genetic testing, meeting diverse reproductive genetic diagnostic needs.

Top Strategies Followed by Global Non-invasive Prenatal Testing (NIPT) Market Players

• Established Players: Leading companies are heavily investing in research and development to innovate high-performance NIPT products.
  • For instance, Illumina has been at the forefront of advancing sequencing technologies to enhance the accuracy and efficiency of NIPT. Their continuous R&D efforts have led to the development of more reliable and comprehensive prenatal testing solutions.
• Mid-Level Players: Mid-level players focus on delivering quality, budget-friendly NIPT products targeting price-sensitive consumers. A notable example is the introduction of more affordable NIPT options by companies like Natera, aiming to make prenatal testing accessible to a wider demographic.
• Small-Scale Players: Small players often target niche markets with unique features or innovative products.
  • For instance, Cradle Genomics focuses on developing advanced NIPT solutions that can be administered earlier in pregnancy, catering to specific market needs.

Emerging Startups - Non-invasive Prenatal Testing (NIPT) Industry Ecosystem

• Innovative Technologies: DNAscript is developing programmable molecular assemblers to synthesize personalized molecular circuits for compact sequencing. This could miniaturize NIPT devices. Cygenica uses graph neural networks for structural variant detection in NIPT, improving diagnostic accuracy.
• Sustainable Solutions: Cradle Genomics aims to make NIPT disposables plastic-free and fully recycled/compostable to reduce medical waste. It uses biodegradable substrates and vegetable-based inks for kits. Prelude Genetics captures fetal cells from maternal blood through microfluidic-based separation without centrifugation, lowering energy usage 50%. Their technologies set sustainability standards.
• Market Contribution: Startups like Juno Diagnostics are addressing unique market needs by developing NIPT solutions that are more accessible and affordable, targeting underserved populations. Partnerships with other companies or institutions drive technological and sustainable innovation. For instance, in February 2023, Juno Diagnostics partnered with Labcorp to expand the availability of its NIPT solutions, enhancing market reach and technological advancements.